Showing promise in the landscape of obesity management, retatrutide represents a distinct approach. Beyond many existing medications, retatrutide functions as a twin agonist, concurrently engaging both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. This simultaneous activation encourages several helpful ef